- Pliant Therapeutics Inc INTEGRIS-PSC Phase 2a Trial Results Call TranscriptFeb 05, 2024
- Pliant Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 09, 2024
- Pliant Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 28, 2023
- Pliant Therapeutics Inc INTEGRIS-PSC Interim Phase 2a Data Presentation TranscriptSep 26, 2023
- Pliant Therapeutics Inc at Canaccord Genuity Growth Conference TranscriptAug 10, 2023
- Pliant Therapeutics Inc at RBC Capital Markets Global Healthcare Conference TranscriptMay 17, 2023
- Pliant Therapeutics Inc INTEGRIS-IPF Call TranscriptMay 01, 2023
- Pliant Therapeutics Inc at Needham Healthcare Conference (Virtual) TranscriptApr 19, 2023
- Pliant Therapeutics Inc at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 13, 2023
- Pliant Therapeutics Inc at Cowen Health Care Conference TranscriptMar 08, 2023
- Pliant Therapeutics Inc at SVB Securities Global Biopharma Conference (Virtual) TranscriptFeb 15, 2023
- Pliant Therapeutics Inc Review Data from the 320 mg Group of the INTEGRIS-IPF Phase 2a Trial of Bexotegrast (PLN-74809) in Patients with IPF Call TranscriptJan 23, 2023
- Pliant Therapeutics Inc at Piper Sandler Healthcare Conference TranscriptNov 30, 2022
- Pliant Therapeutics Inc at Evercore ISI HealthCONx Conference (Virtual) TranscriptNov 29, 2022
- Pliant Therapeutics Inc at RBC Capital Markets Biotech Expert Insights: Pulmonary/Lung Disease Mini-Symposium (Virtual) TranscriptOct 07, 2022
- Pliant Therapeutics Inc to Discuss Results from INTEGRIS-IPF Call TranscriptJul 11, 2022
- Pliant Therapeutics Inc Annual Shareholders Meeting TranscriptJun 16, 2022
- Pliant Therapeutics Inc at RBC Capital Markets Global Healthcare Conference TranscriptMay 18, 2022
- Pliant Therapeutics Inc at Needham Healthcare Conference (Virtual) TranscriptApr 12, 2022
Pliant Therapeutics Inc INTEGRIS-IPF Call Transcript
Good morning, and thank you for joining Pliant Therapeutics' Conference Call. (Operator Instructions). Please be advised that today's conference is being recorded. I would like to turn the call over to Christopher Keenan, Pliant Therapeutics' Vice President and Investor Relations. Mr. Keenan?
Thank you, Shannon, and good morning, everyone. Thank you for joining us for Pliant's presentation of 24-week data from the INTEGRIS-IPF trial, our Phase 2 clinical trial evaluating Bexotegrast, formerly PLN74809, at 320 milligrams in patients with idiopathic pulmonary fibrosis. Yesterday, we issued a press release that will be referenced during this call and is available under the Investor and Media section of our corporate website. The slides accompanying today's webcast are also available in the same section.
During today's call, we will be making forward-looking statements, including those related to the therapeutic potential of Bexotegrast and our plans for the future
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)